ISBT - Scientific Programme

3/26/2018 ISBT: Scientific Programme
Scientific programme
Scientific programme
This Congress will showcase a plethora of relevant topics in
the exciting field of Transfusion Medicine, from recruitment of
blood donors to the actual donation process, biology of blood
cells, preparation of blood components, transfusion-
transmitted infectious diseases, immunohaematology patient
blood management, adverse transfusion events, cellular
therapies, and much more. Follow the ISBT announcements
for more information about Workshops and special sessions,
such as the Young Investigator Breakfast Sessions.
The Local Day will be organised by the Canadian Society of
Transfusion Medicine and will focus on 200 years of
Transfusion Medicine. More information about the
programme of the Local Day, the ISBT Academy Day and the
parallel sessions will be made available on this page.
Simultaneous translation
On the Local Day (Saturday June 2) and Academy Day
(Sunday June 3) simultaneous translation will be provided for
French Canadians.
Young Investigators Breakfast

On Tuesday June 5, 2018 a breakfast is organized to
informally bring Young Investigators (under 40 years old)
together with Transfusion Medicine experts. The breakfast is
held in room 401 in the Metro Convention Centre, Toronto.
For more information click here.
Transfusion Practitioners
On Monday June 4, 2018 a networking breakfast is organized
to bring Transfusion Practitioners together to meet new
colleagues and share ideas. The breakfast is held in room
401 in the Metro Convention Centre, Toronto.
For more information click here.
http://isbtweb.org/toronto/scientific-programme/ 1/24
PROGRAMME PER DAY **

Saturday, June 2 (Local Day)
Saturday, 08.00 - 10.30 hrs
11.00 - History of transfusion medicine in

12.00 Canada
John Freedman
12.00 - Lunch
13.00
13.00 - The Canadian Blood Services turn 20:

14.00 past, present and future
Graham Sher
14.00 - NAC/CCNMT update

14.30 Jennifer Fesser and Heather Hume
14.30 - From serology to genotyping and

15.15 updates in testing
Gwen Clarke
15.15- Break
15.30
15.15 - Introduction to the new products

16.00 Dana Devine
16.00 Novel approaches to teaching

-16.45 transfusion medicine
Yulia Lin
16.45 - Cellular therapy comes of age

17.30 Donna Wall
17.30 Adjourn
Sunday, June 3 (ISBT Academy Day)
Sunday, 09.00 - 10.30 hrs
09.00 - Donors & Donation

10.30
09.00 - Donor eligibility and selection for

09.30 apheresis
C. Poole (South Africa)
09.30 - Short and longer-term risk of donor

10.00 apheresis
M. Neyrinck (Belgium)
10.00 - Establishing an apheresis service in a

10.30 resource-limited setting
B. Pheng (Cambodia)
09.00 - Education and Training
10.30
09.00 - Using simulation for training in clinical

10.30 transfusion medicine
A. Petrosoniak & K. Pavenski (Canada
10.30 - Coffee break

11.00
Sunday, 11.00 - 12.30 hrs
11.00 Organisation and Quality

-
12.30
11.00 Quality: what I know now that I wish I'd

- known then
11.30 M. Smith (New Zealand)
11.30 Training the quality team

- L. Bust (South Africa)
12.00
12.00 When things go badly: managing quality

- problems and complaints in transfusion
12.30 medicine
T. Vuk (Croatia)
11.00 Transfusion-transmitted infectious

- diseases
12.30
11.00 Introducing the I TRY IT program

- B. Custer (USA)
11.30
11.30 I TRY IT programme participants

- I TRY IT Participants (Various)
11.45
11.45 Discussion
-
12.30
12.00 Satellite Symposia

-
13.30
12.30 Lunch Break

-
13.30
Sunday, 13.30 - 15.00 hrs
13.30 Immunohaematology
-
15.00
13.30 What's new in the Kell and Gerbich blood

- group systems
14.00 P. Ligthart (Netherlands)
14.00 And now there are 49: update on the

- MNS blood group system
14.30 C. Gassner (Switzerland)
14.30 Kidd blood group system: only 3 antigens

- but what about the variants?
15.00 J. Hamilton (USA)
13.30 Clinical transfusion practice

-
15.00
13.30 What is ECMO, and why do we use it in

- critical illness?
14.00 To be confirmed
14.00 Is it TACO, TRALI or something else?

- M. Looney (USA)
14.30
14.30 None too SMAll: the global challenge of

- severe malarial anaemia and its
15.00 transfusion support
C. Cserti-Gazdewich (Canada)
15.00 Break
-
15.30
Sunday, 15.30 - 21.00 hrs
15.30 Immunohaematology
-
17.00
15.30 After 70 years, serological RhD

- determination is still challenging: DNA to
16.00 the rescue
M. Pisacka (Czech Republic)
16.00 Getting comfortable with Rh blood group

- system terminologies and databases
16.30 F. Werner (Germany)
16.30 Decision-making in complex obstetric

- cases: How to end up with a healthy bab
17.00 in HDFN
M. Delaney (USA)
15.30 Cellular therapies and haemovigilance

-
17.00
15.30 Microbial Safety of Cellular Therapeutics

- Lessons from over ten years experience
16.00 in microbial safety of platelet concentrate
M. Störmer (Germany)
16.00 Adverse outcomes and substances of

- human origin: Cases from the NOTIFY
16.30 Library
E. Petrisli (Italy)
16.30 Safety and surveillance issues in stem

- cell marketing
17.00 D. Sipp (Japan)
17.45 Opening Ceremony & Welcome

- Reception
21.00
Monday, June 4
Monday, 07.00 - 10.30 hrs
07.00 Transfusion Practitioners

-
08.00
Networking Breakfast
08.30 Immunobiology
-
10.00
08.30 Drug induced haemolytic anaemia

- D. Branch (Canada)
09.00
09.00 SELECTED ABSTRACTS

-
10.00
08.30 Clinical
-
10.00
08.30 Challenges in PBM / Tools for PBM
- P. Meybohm (Germany)
09.00
09.00 Questioning the benefit of restrictive

- transfusion practice in older adults
09.30 G. Simon (Australia)
09.30 The outcome of the Patient Blood

- Management Consensus Conference,
10.00 Frankfurt April 2018
M.M. Mueller (Germany)
08.30 Donors and Donation

-
10.00
The effect of iron on fetal and neonatal

brain development
M. Georgieff (USA)
The effect of blood donation of women o

the birth weight of their offspring
H. Ullum (Denmark)
SELECTED ABSTRACTS
08.30 Cellular Therapies

-
10.00
08.30 Cord blood expansion with novel small

- molecule
09.00 G. Sauvageau (Canada)

-
10.00
08.30 WP TTID
-
10.00
Overview of TTI WP mission,

membership and activities
C. Seed (Australia)
Surveillance, risk assessment, and polic

subgroup presentation
S. O'Brien (Canada)
Bacterial subgroup presentation

C. MacDonald (UK)
Parasite subgroup presentation

E. Bloch (USA)
08.30 WP IT
-
10.00
Electronic identity control, replacement

identification and multiple transfusions
made easy in the OR/ER
J. Georgsen (Denmark)
Visibility and access to blood products

via technology
L. Briggs (USA)
Practical consideration in implementing

RFID for the blood supply
S. Lam (Singapore)
10.00 Coffee break

-
10.30
Monday, 10.30 - 12.00 hrs - Plenary Session
10.30 - Plenary Session: Arboviruses

12.00
10.30 - Insect disease vectors and their impac

12.00 on human health
L. Harrington (USA)
10.30 - Malarial resistance

12.00 E. Leftler (UK)
10.30 - The immune role of platelets in malari
12.00 B. McMorran (Australia)
12.00 - Satellite Symposia

13.30
12.00 - Lunch break

14.00
Monday, 14.00 - 15.30 hrs
14.00 - Donors & donation

15.30
14.00 - Donor vasovagal reactions, how can

14.30 we reduce them?
J. Castren (Finland)
14.30 - SELECTED ABSTRACTS

15.30
14.00 - Blood products

15.30
14.00 - Novel platelet products

14.30 R. Cardigan (UK)

15.30
14.00 - Blood safety

15.30
14.00 - Bacterial contamination - CBS

14.30 experience
S. Ramirez Arcos (Canada)

15.30
14.00 - Management & Organisation

15.30
14.00 - Emergency preparedness for mass

14.30 casualty events
H. Doughty (UK)

15.30
14.00 - Transfusion Practitioners

15.30
14.00 - The Transfusion Practitioner and

14.30 disaster planning
R. Deelen (Netherlands)
14.30 - The Transfusion Practitioner role in

15.00 minimising blood wastage
L. Bielby (Australia)
15.00 - Is ONTraC on track? A fifteen year

15.30 experience
A. Howell (Canada)
14.00 - Young investigators session

15.30

15.30

16.00
Monday, 16.00 - 17.30 hrs
16.00 Cellular therapies

-
17.30
16.00 The use of cord blood in metabolic

- disorders and hypoxic brain injuries
17.30 J. Kurtzberg (USA)

-
17.30
16.00 Blood products

-
17.30
16.00 Pathogen inactivation technologies

- D. Devine (Canada)
17.30

-
17.30
16.00 Safety
-
17.30
16.00 Donor history questionnaire – Pakistan

- I. Shabber (Pakistan)
16.30
16.30 Addressing Transfusion Transmitted

- malaria in Kenya
17.00 V. Magutu (Kenya)
17.00 To be announced
-
17.30
16.00 Immunobiology
-
17.30
To be announced
16.00 Clinical
-
17.30
16.00 Transfusion of neonates: evidence &

- complications
16.30 A. Keir (Australia)

-
17.30
16.00 WP Donors and donation

-
17.30
Complications of blood donation

C. Napoli (Italy)
Needle comlications
M. Townsend (USA)
Apheresis comlications
H. Vrielink (Netherlands)
Tuesday, June 5
Tuesday, 08.30 - 12.00 hrs
08.30 - Jean Julliard Prize

09.30
08.30 - Introductory presentation

09.30
09.00 - Jean Julliard Prize Lecture

09.30 R. Kapur (Sweden)

10.00
10.00 - Presidential Award Session

11.30
10.00 - Opening
10.15
10.05 - Laudation
10.15 H. Reesink (Netherlands)
10.15 - Historical overview to prevent blood

10.35 transmissible infectious agents
H. Alter (USA)
10.35 - Impact of hepatitis E virus infection on

10.55 the safety of the blood supply
H. Zaaijer (Netherlands)
10.55 - Estimating risk and evaluating efficacy

11.25 of risk reduction strategies
M. Busch (USA)
11.25 - Award Ceremony

11.30
11.45 - ISBT General Assembly

12.30 Members of ISBT only

13.30
12.00 - Lunch break

14.00
Tuesday, 14.00 - 15.30 hrs
14.00 Donors & Donation

-
15.30
14.00 MSM and blood donation

- S. Sauleda (Spain)
14.30

-
15.30
14.00 Blood Products

-
15.30
14.00 All about frozen platelets

- M. Reade (Australia)
14.30

-
15.30
14.00 Safety
-
15.30
14.00 Indian experience of introducing a

- haemovigilance scheme
14.30 A. Bist (India)

-
15.30
14.00 Immunobiology
-
15.30
14.00 The role of molecular genotyping - a new

- era
14.30 N. Gleadall (UK)

-
15.30
14.00 Blood supply

-
15.30
14.00 Towards a safe and sufficient blood

- supply in Africa
14.30 D. Kyeyune (Uganda)

-
15.30
14.00 Tranfusion Practitioners

-
15.30
14.00 ISBT Transfusion Practitioners survey

- feedback
14.30 A. Dhesi (UK) and R. Deelen
(Netherlands)
14.30 Selected TP Abstracts

-
15.30
14.00 WP Cellular Therapy

-
15.30
The current status of human platelet

lysate production and manufacturing
T. Burnouf (Taiwan)
Platelet based clinical therapies: where

are we now?
C. Cohn (USA)
Novel new platelet derived products:

science, regulation and the evolving role
of blood banks
M. Koh (UK/Singapore)
15.30 Coffee break

-
16.00
Tuesday, 16.00 - 17.30 hrs
16.00 Donors & Donation

-
17.30
16.00 Donor health

- E. Di Angelantonio (UK)
16.30

-
17.30
16.00 Management & Organisation

-
17.30
16.00 The challenges of implementing the Euro

- good practice guidelines for blood
16.30 components
J. Bikulciené (Lithuania)
16.30 Development of standards and accredita

- Africa
17.00 C. Tayou (Cameroon)

-
17.30
16.00 Immunobiology
-
17.30
16.00 ITP pathophysiology

- M. Michel (France)
16.30
16.30 TACO pathophysiology

- R. Kapur (Sweden)
17.00
16.00 Clinical
-
17.30
16.00 Prevention & management of RBC

- Alloimmunisation in thalassemia
16.30 A.A. Pourfathollah (Iran)

-
17.30
16.00 WP Rare
- donors/terminology/immunohematolo
17.30
Introduction
N. Thornton (UK)
Name that specificity: investigating and

identifying complex and exotic Rh varian
T. Peyrard (France)
Making it all happen for patients with rare

blood
V. Yahalom (Israel)
Cataloging blood group variation with the

of new tools
M.L. Olsson (Sweden)
16.00 WP Blood supply management

-
17.30
Effective cold chain management

R. Tocchetti (Australia)
Outcome of survey on blood product was

in developing countries
M. Yazer (USA)
Challenges to emergency transfusion in

developing/resource constrained countrie
D. Kyeyune (Uganda)
17.45 Poster session

-
18.45
Wednesday, June 6
Wednesday, 08.30 - 10.00 hrs
08.30 Donors and Donation

-
10.00
08.30 An overview of donor base models in

- Sub-Sahara Africa: challenges and
09.00 successes
I. Bates (UK)
09.00 Building a blood system: the view froum
- Saudi Arabia
09.30 M. Badawi (Saudi Arabia)

-
10.00
08.30 Blood products

-
10.00
08.30 Automated products

- J. Cid (Spain)
09.00

-
10.00
08.30 Viruses
-
10.00
08.30 Splenic Macrophage Subsets and Their

- Functioning during Blood-Borne Infection
09.00 D'Imperio Lima (Brazil)

-
10.00
08.30 Immunobiology
-
10.00
08.30 The significance of altered IgG-

- glycosylation in Transfusion Medicine
09.00 G. Vidarsson (Netherlands)

-
10.00
08.30 Cellular therapy

-
10.00
08.30 Lowering transfusion thresholds in

- haematopoetic stem cell transplantation
09.00 A. Tinmouth (Canada)

-
10.00
08.30 Clinical
-
10.00
08.30 Improving efficacy of audit and feedback

- to improve transfusion practice
09.00 S. Stanworth (UK)

-
10.00
10.00 Coffee break

-
10.30
Wednesday, 10.30 - 12.00 hrs (Plenary Session)
10.30 - Plenary Session: Platelets

12.00
10.30 - In vitro production of platelets

11.00 J. Thon (USA)
11.00 - Novel roles for platelets in health an

11.30 disease
M. Rondina (USA)
11.30 - Prevention of HLA alloimmune

12.00 refractoriness
K. Pavenski (Canada)

13.30
12.00 - Lunch break

13.30
13.30 Donor Recruitment

-
15.00
13.30 Recruitment and retention

- To be announced
14.00
- To be announced
14.30
- To be announced
15.00
13.30 Products
-
15.00
13.30 The Effect of Sex and Age of the Donor

- on the Outcome of Transfusion Recipient
14.00 G. Edgren (Sweden)
14.00 The Effect of Sex and Age of the Donor

- on the Outcome of Transfusion Recipient
14.30 R. Middelburg (Netherlands)

-
15.00
13.30 WP Clinical - paediatric subgroup

-
15.00
13.30 Big Data applications in Pediatric

- Transfusion: size matters!
14.00 R. Goel (USA)
14.00 Epidemiology: practice patterns and

- outcomes for children transfused for life
14.30 threatening haemorrhage
P. Spinella (USA)
14.30 Neonatal and paediatric haemovigilance

- H. New (UK)
15.00
13.30 Immunobiology
-
15.00

-
15.00
13.30 Safety
-
15.00
13.30 Emerging infectious diseases

- C. Erikstrup (Denmark)
14.00

-
15.00
13.30 WP Platelet
-
15.00
New discoveries in immune mediated

thrombocytopenia: implications for
diagnosis and therapy
H. Ni (Canada)
Platelet serology for allo and

autoantibodies: pivotal or just nice to
have?
U. Sachs (Germany)
Report on the 19th International Platelet

Immunology workshop
L. Richard (Canada)
Generation of HPA-matched platelet

precursors from humans iPS cells using
CRISPR-mediated genome engineering
P. Newman (USA)
15.00 Coffee Break

-
15.30
15.30 - Plenary session - Transfusion

17.30 Medicine past, present and future
15.30 - Past
16.00 D. Starr (USA)
16.00 - Present
16.30 S. Dzik (USA)
16.30 - Future
17.00 To be confirmed
17.00 - Surprise speaker

17.30
17.30 Closing ceremony
20.00 - Congress Party / Banquet

23.00
Young Investigator (YI) Networking Breakfast
** Each parallel session will comprise (an) invited speaker(s)

and selected abstracts for oral presentation.

ISBT - Scientific Programme

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

ISBT - Scientific Programme

Uploaded by

Copyright:

Available Formats

3/26/2018 ISBT: Scientific Programme

Young Investigators Breakfast

PROGRAMME PER DAY **

Saturday, 08.00 - 10.30 hrs

Saturday, 11.00 - 13.00 hrs

11.00 - History of transfusion medicine in

Saturday, 13.00 - 15.30 hrs

13.00 - The Canadian Blood Services turn 20:

14.00 - NAC/CCNMT update

14.30 - From serology to genotyping and

Saturday, 15.30 - 17.30 hrs

15.15 - Introduction to the new products

16.00 Novel approaches to teaching

16.45 - Cellular therapy comes of age

Sunday, June 3 (ISBT Academy Day)

Sunday, 09.00 - 10.30 hrs

09.00 - Donors & Donation

09.00 - Donor eligibility and selection for

09.30 - Short and longer-term risk of donor

10.00 - Establishing an apheresis service in a

09.00 - Education and Training

09.00 - Using simulation for training in clinical

10.30 - Coffee break

Sunday, 11.00 - 12.30 hrs

11.00 Organisation and Quality

11.00 Quality: what I know now that I wish I'd

11.30 Training the quality team

12.00 When things go badly: managing quality

11.00 Transfusion-transmitted infectious

11.00 Introducing the I TRY IT program

11.30 I TRY IT programme participants

12.00 Satellite Symposia

12.30 Lunch Break

Sunday, 13.30 - 15.00 hrs

13.30 What's new in the Kell and Gerbich blood

14.00 And now there are 49: update on the

14.30 Kidd blood group system: only 3 antigens

13.30 Clinical transfusion practice

13.30 What is ECMO, and why do we use it in

14.00 Is it TACO, TRALI or something else?

14.30 None too SMAll: the global challenge of

Sunday, 15.30 - 21.00 hrs

15.30 After 70 years, serological RhD

16.00 Getting comfortable with Rh blood group

16.30 Decision-making in complex obstetric

15.30 Cellular therapies and haemovigilance

15.30 Microbial Safety of Cellular Therapeutics

16.00 Adverse outcomes and substances of

16.30 Safety and surveillance issues in stem

17.45 Opening Ceremony & Welcome

Monday, 07.00 - 10.30 hrs

07.00 Transfusion Practitioners

08.30 Drug induced haemolytic anaemia

09.00 SELECTED ABSTRACTS

08.30 Challenges in PBM / Tools for PBM

09.00 Questioning the benefit of restrictive

09.30 The outcome of the Patient Blood

08.30 Donors and Donation

The effect of iron on fetal and neonatal

The effect of blood donation of women o

08.30 Cellular Therapies

08.30 Cord blood expansion with novel small

09.00 SELECTED ABSTRACTS